Targeting EZH2 in cancer
KH Kim, CWM Roberts - Nature medicine, 2016 - nature.com
Recent genomic studies have resulted in an emerging understanding of the role of
chromatin regulators in the development of cancer. EZH2, a histone methyl transferase …
chromatin regulators in the development of cancer. EZH2, a histone methyl transferase …
Adenoid cystic carcinoma: a review of recent advances, molecular targets, and clinical trials
PM Dillon, S Chakraborty, CA Moskaluk, PJ Joshi… - Head & …, 2016 - Wiley Online Library
Background Adenoid cystic carcinoma (ACC) is a rare tumor of secretory glands. In this
study, recent advances in molecular characterization and in therapeutics are reviewed …
study, recent advances in molecular characterization and in therapeutics are reviewed …
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity
MT Chang, S Asthana, SP Gao, BH Lee… - Nature …, 2016 - nature.com
Mutational hotspots indicate selective pressure across a population of tumor samples, but
their prevalence within and across cancer types is incompletely characterized. An approach …
their prevalence within and across cancer types is incompletely characterized. An approach …
Recurrent Fusions in MYB and MYBL1 Define a Common, Transcription Factor–Driven Oncogenic Pathway in Salivary Gland Adenoid Cystic Carcinoma
Adenoid cystic carcinoma (ACC), the second most common malignancy of salivary glands, is
a rare tumor with a bleak prognosis for which therapeutic targets are unavailable. We used …
a rare tumor with a bleak prognosis for which therapeutic targets are unavailable. We used …
An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma
Y Drier, MJ Cotton, KE Williamson, SM Gillespie… - Nature …, 2016 - nature.com
Translocation events are frequent in cancer and may create chimeric fusions or'regulatory
rearrangements' that drive oncogene overexpression. Here we identify super-enhancer …
rearrangements' that drive oncogene overexpression. Here we identify super-enhancer …
Novel MYBL1 Gene Rearrangements with Recurrent MYBL1–NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations
Purpose: Adenoid cystic carcinoma (ACC) is an indolent salivary gland malignancy,
characterized by t (6; 9) translocations and MYB–NFIB gene fusions in approximately 50% of …
characterized by t (6; 9) translocations and MYB–NFIB gene fusions in approximately 50% of …
[HTML][HTML] Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants
Triple-negative breast cancers (TNBCs), defined by lack of expression of estrogen receptor,
progesterone receptor and HER2, account for 12–17% of breast cancers and are clinically …
progesterone receptor and HER2, account for 12–17% of breast cancers and are clinically …
Comprehensive molecular characterization of salivary duct carcinoma reveals actionable targets and similarity to apocrine breast cancer
MG Dalin, A Desrichard, N Katabi, V Makarov… - Clinical cancer …, 2016 - AACR
Purpose: Salivary duct carcinoma (SDC) is an aggressive salivary malignancy, which is
resistant to chemotherapy and has high mortality rates. We investigated the molecular …
resistant to chemotherapy and has high mortality rates. We investigated the molecular …
MLL3/MLL4/COMPASS family on epigenetic regulation of enhancer function and cancer
CC Sze, A Shilatifard - Cold Spring …, 2016 - perspectivesinmedicine.cshlp.org
During development, precise spatiotemporal patterns of gene expression are coordinately
controlled by cis-regulatory modules known as enhancers. Their crucial role in development …
controlled by cis-regulatory modules known as enhancers. Their crucial role in development …
Uterine adenosarcomas are mesenchymal neoplasms
Uterine adenosarcomas (UAs) are biphasic lesions composed of a malignant mesenchymal
(ie stromal) component and an epithelial component. UAs are generally low‐grade and …
(ie stromal) component and an epithelial component. UAs are generally low‐grade and …